Management of pancreatitis related to Bortezomib treatment: report of two cases

Brulc, Erika; Seehaus, Cristian; Schütz, Natalia; Fantl, Dorotea

doi:10.1016/j.htct.2018.03.003

Cited by 4 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have also highlighted six cases that have experienced positive rechallenge for four imputable drugs known to be associated with AP. Among them, one drug (bortezomib) has numerous documented cases of positive rechallenge [ 28 – 30 ]. In fact, it is well known that pancreatitis is a rare ADR of this antineoplastic agent.…”

Section: Discussionmentioning

confidence: 99%

A Drug-Induced Acute Pancreatitis Retrospective Study

Gagnon

Lavoie

Frigon

et al. 2020

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

Background and Aims. Drugs are considered a relatively rare and understudied cause of acute pancreatitis (AP). The lack of convincing and conclusive data on drug-induced AP (DIAP) complicates the diagnosis as well as the identification of the causative drug. The aim of this study is to document causes of DIAP cases that occurred in the Saguenay-Lac-Saint-Jean (SLSJ) population. Methods. We have conducted a retrospective and descriptive population-based study of DIAP cases that occurred between 2006 and 2014 in the six hospitals serving the entire SLSJ population. Cases were selected from the Quebec Ministry of Health hospitalizations registry (MED-ECHO) administrative public database. A medical chart review was performed in an attempt to characterize DIAP hospitalizations and to identify the imputable drugs. Results. During the studied period, 75 cases (30.7% male, 69.3% female) were included totaling 90 hospitalizations for DIAP. Among them, 50 causative drugs were identified and were distributed in 17 different drug classes. Recurrent DIAPs were documented in 13 cases, and among them, 6 cases have experimented a positive rechallenge. Six drugs (5-fluorouracil, atorvastatin, bortezomib, nilotinib, rosuvastatin, and triamcinolone) were associated with the highest degree of evidence. The most common causative drugs of DIAP hospitalization were azathioprine (n = 7), followed by atorvastatin (n = 6), hydrochlorothiazide (n = 5), rosuvastatin (n = 4), and codeine (n = 4). Conclusions. This study has added new evidences about potentially pancreatitis-associated drugs in literature. This is the first study to report definite 5-fluorouracil- and triamcinolone-induced AP. An updated version of the evidence-based literature review is needed to support the clinicians in the identification of the causative drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

A Drug-Induced Acute Pancreatitis Retrospective Study

Gagnon

Lavoie

Frigon

et al. 2020

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

show abstract

“…Its mechanism of action is based on a reversible inhibition of proteasome subunit 26s, thereby inhibiting its chymotrypsin activity. However, this side effect is rare, occurring in 0,1-2% of cases [35]. The mechanism of inflammation is still unknown, but direct drug toxicity or allergic and immunological causes are considered [35].…”

Section: Acute Pancreatitis As a Side Effect Of Drugs Used In Pediatr...mentioning

confidence: 99%

“…However, this side effect is rare, occurring in 0,1-2% of cases [35]. The mechanism of inflammation is still unknown, but direct drug toxicity or allergic and immunological causes are considered [35]. Elevation of pancreatic enzymes is observed chiefly a few days after drug administration.…”

Section: Acute Pancreatitis As a Side Effect Of Drugs Used In Pediatr...mentioning

confidence: 99%

See 1 more Smart Citation

Case Report: Brentuximab Vedotin Associated Acute Pancreatitis in a Pediatric Hodgkin Lymphoma Patient: Case Report and Literature Review

Truszkowska¹,

Andrzejewska²,

Szymańska³

et al. 2022

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Brentuximab vedotin is a conjugate drug used mainly in Hodgkin lymphoma, systemic and primary cutaneous anaplastic large cell lymphomas, and CD30-expressing peripheral T-cell lymphoma. We report a unique case of acute pancreatitis associated with brentuximab vedotin in a 17-year-old male patient suffering from classical Hodgkin lymphoma. Diagnosed in 2020, the patient was classified to an intermediate therapeutic group and disease’s grade was IIIAE. The patient was treated with brentuximab vedotin and bendamustine in the third line. Two weeks after the drug administration, the patient developed acute epigastric pain. Laboratory and radiological findings confirmed the clinical suspicion of acute pancreatitis that was managed with opioid pain medications, meropenem, parenteral nutrition, ondansetron and omeprazole. This is the first case report of brentuximab vedotin-associated acute pancreatitis in the pediatric patient reported in the literature to the best of our knowledge.

show abstract

“…Recent case reports have linked the newer tyrosine kinase inhibitors (TKIs), vemurafenib and ponatinib to pancreatitis and just elevated pancreatic enzymes. The famous proteasome inhibitor, bortezomib, has been repeatedly reported to cause pancreatitis [33].…”

Section: Anticancer Therapiesmentioning

confidence: 99%

Updates in drug-induced acute pancreatitis

Alhaddad

Elsabaawy

Elfauomy

et al. 2020

Egypt Liver Journal

View full text Add to dashboard Cite

Background Being infrequent, drug-induced acute pancreatitis (DIP) is an overlooked clinical entity that can be serious with significant morbidity and mortality. Main body A renovative review of drugs incriminated in acute pancreatitis had been presented with all relevant data and case presentations. Antibiotics, antidiabetics, antihypertensive agents, H2 blockers (H2B) and proton pump inhibitors (PPIs), anticancer therapies, and the new direct-acting antiviral therapies (DAAs) of hepatitis C virus (HCV) were discussed pertinently to DIP. Conclusions DIP should be suspected as a potential adverse event to every newly emerged drug. Herein, an updated review of drugs recently alleged to be implicated in DIP.

show abstract

Management of pancreatitis related to Bortezomib treatment: report of two cases

Cited by 4 publications

References 7 publications

A Drug-Induced Acute Pancreatitis Retrospective Study

A Drug-Induced Acute Pancreatitis Retrospective Study

Case Report: Brentuximab Vedotin Associated Acute Pancreatitis in a Pediatric Hodgkin Lymphoma Patient: Case Report and Literature Review

Updates in drug-induced acute pancreatitis

Contact Info

Product

Resources

About